Loading... Please wait...
About Us
Contact Us
Privacy Policy
Sign in
or
Create an account
My Account
View Basket
Checkout
Search
Home
Report Subject
Market Access
Browse by
Biosimilar Index
Dossier
FirstView
FirstView NPS+
FirstWord Pharma
Therapy Trends
Therapy Trends Updates
Latest Reports
Therapy Area Reports
Report Subject
Emerging Markets
Generics/Biosimilars
Market Access
Medical Affairs
Pharma Marketing
Pharma Sales
Technology/Digital Health
Orphan Drugs
Sort by:
Featured Items
Newest Items
Bestselling
Alphabetical: A to Z
Alphabetical: Z to A
Next »
Pages:
1
2
3
4
5
6
Learn More
The Future of Key Account Management in Pharma
Are you ready for fundamental disruption to key account management practice? While the Key Account Management (KAM) role will continue to prioritise the development of long-term, sustainable partnerships between...
Compare
Learn More
Benchmarking Key Account Management Capabilities (2019)
What factors determine a Key Account Manager (KAM) team's size and structure? At what stage in a product's lifecycle are KAMs assigned and how many brands should a typical KAM support? What personal attributes and...
Compare
Learn More
Real-World Data Capabilities: Benchmarking Pharma Companies (2019)
Are you fully and efficiently exploiting real-world data across your business? The impact of real-world data (RWD) is growing but few companies are fully exploiting its potential across all clinical and commercial areas...
Compare
Learn More
KAM Metrics: Measuring Success (2019)
Secure a successful future for your KAM teams by proving their true value KAM teams are still evolving but they're also concerned about their future. They need appropriate measures to demonstrate their true value...
Compare
Learn More
Indication-level Pricing: Payer Insights
Can pharma persuade payers of the benefits of indication-level pricing? Advocates argue that indication-level pricing can bring new products on stream and results in wider patient access to new therapies. That's a good...
Compare
Learn More
Real World Data and Evidence: Payer Insights
Payers have great expectations for real world data. Is pharma meeting them? It's sink or swim time. Advancements in drug data collection methodologies and deeper understanding of what can be achieved has finally opened...
Compare
Learn More
Review of Influence: The Institute for Clinical and Economic Review (ICER)
As the Institute for Clinical and Economic Review's (ICER) influence on payer behaviour and health policy grows, how should pharma respond? The ICER's novel and inclusive work on the value of drugs, using its own value...
Compare
Learn More
Pharma-Tech Partnerships: Key Success Factors
What does an ideal Pharma-Tech partnership look like? Learn from Merck, Sanofi, Boehringer Ingelheim and UCB With tech companies making their presence felt in the health market and a demand for greater efficiency...
Compare
Learn More
Commercialisation of Biosimilars: Current Best Practice and Future Trends
The key to commercial success for biosimilars? Find out what the experts say The biosimilars market is in a state of flux as key players in the US and Europe actively seek to improve perceptions, shape the market, and...
Compare
Learn More
The State of Pharma Digital Transformation
How digitally mature is pharma? What progress has pharma made to embrace the digital age? Are digital strategies robust enough? Are appropriate capabilities and organisational structures in place? How culturally ready...
Compare
Learn More
Time to Market: Accelerating Market Access
Building the most effective strategy for fast track market access Getting to market faster clearly has benefits, but there are also potential downsides for drug companies too. You need to know the options and consider...
Compare
Learn More
A new Era in Pharma Marketing: Delivering Content-Driven Experiences
Are you locked in a traditional product marketing mind set? Time to move on... How can you provide better support and awareness to HCPs and patients for your brands? Content marketing may be the answer. Advocates argue...
Compare
Learn More
Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era
The biologics competitive landscape is at a critical stage of development. How will you respond? Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete...
Compare
Learn More
Pharma-patient engagement: Patient centricity comes of age
Are you truly patient-centric or just ticking boxes? Find out how your strategy compares Until relatively recently, patient centricity was commonly seen as just a useful talking point and the catalyst for some...
Compare
Learn More
Orphan Drugs: US Payer Perspectives
So what will persuade US payers to better support orphan drugs? US payer concern at the number of new orphan drugs coming to market, often with eye watering prices attached, can obscure a more positive message: payers...
Compare
Learn More
Orphan Drugs: European Payer Perspectives
European payers reveal how pharma can build trust and gain their support for orphan drug products European payers are concerned about orphan drugs citing unjustified high prices and a lack of evidence of utility and...
Compare
Next »
Pages:
1
2
3
4
5
6
About Us
Contact Us
Privacy Policy
customer.service@firstwordpharma.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved